

Targeted Treatment in Colorectal Cancer: New Mechanisms and Agents and the Role of Clinical Trials in Practice

Select Publications

MARSHALL

Bilusic M et al. **A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers.** Gastrointestinal Cancers Symposium 2012;Abstract 458.

De Gramont A et al. **Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years.** *Proc ASCO* 2007;Abstract 4007.

Friedman A, Perrimon N. **Genetic screening for signal transduction in the era of network biology.** *Cell* 2007;128(2):225-31.

Fuchs C et al. **Irinotecan in the treatment of colorectal cancer.** *Cancer Treat Rev* 2006;32(7):491-503.

I-SPY 2 TRIAL: Neoadjuvant and personalized adaptive novel agents to treat breast cancer. **NCT01042379**

National Comprehensive Cancer Network (NCCN®). **NCCN clinical practice guidelines in oncology. Colon cancer — Version 2.2010.** Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

Pishvaian MJ et al. **A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.** *Proc ASCO* 2011;Abstract 3502.

Timmerman B et al. **Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis.** *PLoS One* 2010;5(12):e15661.

HECHT

Cassidy J et al. **First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC).** *Proc ESMO* 2006;Abstract LBA3.

Ebos JM et al. **Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.** *Cancer Cell* 2009;15(3):232-9.

Ferrara N et al. **The biology of VEGF and its receptors.** *Nat Med* 2003;9(6):669-76.

Hecht JR et al. **Randomized, placebo-controlled, Phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.** *J Clin Oncol* 2011;29(15):1997-2003.

Hecht JR et al. **Sunitinib plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) vs bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer (MCRC) — Interim results of a randomized, Phase IIB study.** 12th ESMO World Congress on Gastrointestinal Cancer 2010;Abstract 0-0014.

Hurwitz H et al. **Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.** *N Engl J Med* 2004;350(2):2335-42.

Saltz LB et al. **Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized Phase III study.** *J Clin Oncol* 2008;26(12):2013-9.

Van Cutsem E et al. **Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase 3 trial (EFC10262-VELOUR).** 13th ESMO World Congress on Gastrointestinal Cancer 2011;Abstract 0-0024.

ARNOLD

Fischer C et al. **FLT1 and its ligands VEGFB and PIGF: Drug targets for anti-angiogenic therapy?** *Nat Cancer Rev* 2008;8(12):942-56.

Giantonio BJ et al. **Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200.** *J Clin Oncol* 2007;25(12):1539-44.

Holash J et al. **VEGF-Trap: A VEGF blocker with potent antitumor effects.** *Proc Natl Acad Sci* 2002;99(17):11393-8.

Jain RK. **Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer.** *Nat Rev Cancer* 2008;8(4):309-16.

Kopetz S et al. **Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.** *J Clin Oncol* 2010;28(3):453-9.

Lieu C et al. **Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis.** *Clin Cancer Res* 2011;17(19):6130-9.

Loupakis F et al. **Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.** *Br J Cancer* 2011;104(8):1262-9.

Tabernero J et al. **Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer.** European Multidisciplinary Congress 2011;Abstract 6LBA.

Tew WP et al. **Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.** *Clin Cancer Res* 2010;16(1):358-66.

ENG

Amado RG et al. **Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.** *J Clin Oncol* 2008;26(10):1626-34.

Benvenuti S et al. **Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.** *Can Res* 2007;67(6):2643-8.

Bessudo A et al. **Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.** *Proc ASCO* 2011;Abstract 3582.

Chapman PB et al. **Improved survival with vemurafenib in melanoma with BRAF V600E mutation.** *N Engl J Med* 2011;364(26):2507-16.

De Roock W et al. **Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.** *JAMA* 2010;304(16):1812-20.

De Roock W et al. **Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis.** *Lancet Oncol* 2010;11(8):753-62.

Eng C et al. **A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses.** *Proc ASCO* 2011;Abstract 3500.

Kopetz S et al. **PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.** *Proc ASCO* 2010;Abstract 3534.

Liu X et al. **Targeting the c-MET signaling pathway for cancer therapy.** *Expert Opin Investig Drugs* 2008;17(7):997-1011.

Zeng Z et al. **c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.** *Cancer Letters* 2008;265(2):258-69.

FISHER

Allegra CJ et al. **Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer.** *Proc ASCO* 2011;Abstract 3508.

Al-Refaie WB et al. **Cancer trials versus the real world in the United States.** *Ann Surg* 2011;254(3):438-43.

Andre T et al. **A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.** *Proc ASCO* 2011;Abstract 3509.

Dilts DM et al. **Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.** *J Clin Oncol* 2009;27(11):1761-6.

Murthy VH et al. **Participation in cancer clinical trials: Race-, sex-, and age-based disparities.** *JAMA* 2004;291(22):2720-6.

Tsimberidou AM et al. **Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative.** *Proc ASCO* 2011;Abstract CRA2500.

Wolmark N et al. **A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP protocol C-08.** *Proc ASCO* 2009;Abstract LBA4.